首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Comparison of clinicopathologic characteristics of urothelial carcinoma between patients after renal transplantation and on dialysis
【24h】

Comparison of clinicopathologic characteristics of urothelial carcinoma between patients after renal transplantation and on dialysis

机译:肾移植术后和透析患者尿路上皮癌临床病理特征的比较

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Urothelial carcinoma (UC) is a common complication after renal replacement therapy (RRT) among Chinese end-stage renal disease (ESRD) patients. It is unclear whether there are any differences in the clinicopathologic characteristics of UC between renal transplantation (RT) and dialysis patients; such differences could impact RRT modality selection. METHODS: We retrospectively reviewed clinicopathologic data for 27 RT patients and 40 dialysis patients who were diagnosed with UC in our center to explore differences in the clinicopathologic characteristics of UC and prognoses between the two groups. RESULTS: The median follow-up period was 92 months (2-137) for the RT group and 71 months (18-155) for the dialysis group. The demographic and baseline data showed no significant differences between the two groups. Upper urinary tract UC (UUC) occurred more frequently in the RT group (22 UUCs in 39 UCs), whereas bladder UC (BUC) predominated in the dialysis group (33 BUCs in 49 UCs) (P=0.025). The pathologic grading in the RT group was significantly higher than that in the dialysis group (P=0.046 for WHO1973 grading, P=0.026 for WHO2004 grading), whereas the difference in tumor stage was not significant (P=0.089). The RT group manifested a higher recurrence rate than the dialysis group (P=0.024). However, the overall and cancer-specific survival rates between the two groups were not significantly different (P=0.239 and P=0.818, respectively). CONCLUSION: Certain traits of UC, including tumor site, pathologic grading, and recurrence-free survival, were notably different between RT and dialysis patients, but the overall and cancer-specific survival rates were similar.
机译:背景:在中国终末期肾脏疾病(ESRD)患者中,肾替代疗法(RRT)后,尿路上皮癌(UC)是一种常见的并发症。目前尚不清楚肾移植和透析患者之间UC的临床病理特征是否存在差异。这种差异可能会影响RRT方式选择。方法:我们回顾性分析了我中心诊断为UC的27例RT患者和40例透析患者的临床病理数据,以探讨UC的临床病理特征和预后的差异。结果:RT组的中位随访期为92个月(2-137),而透析组的中位随访期为71个月(18-155)。人口统计和基线数据显示两组之间没有显着差异。 RT组上尿路UC(UUC)发生率更高(39 UCs中的22个UUC),而透析组(49 UCs中的33个BUC)占主导地位的膀胱UC(BUC)(P = 0.025)。 RT组的病理分级明显高于透析组(WHO1973分级为P = 0.046,WHO2004分级为P = 0.026),而肿瘤分期的差异无统计学意义(P = 0.089)。 RT组的复发率高于透析组(P = 0.024)。但是,两组的总体生存率和癌症特异性生存率没有显着差异(分别为P = 0.239和P = 0.818)。结论:RT和透析患者之间UC的某些特征,包括肿瘤部位,病理分级和无复发生存率显着不同,但总体生存率和癌症特异性生存率相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号